{"database": "lobbying", "table": "lobbying_activities", "rows": [[2067943, "491b1817-a1bb-4b1e-96d7-61e1d30e25c8", "Q4", "EMERGENT BIOSOLUTIONS INC.", 304931, "EMERGENT BIOSOLUTIONS INC", 2017, "fourth_quarter", "DIS", "FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government\nRe-authorization of the Pandemic and All-Hazards Preparedness Act\nNDAA - provisions related to biological and chemical defense", "HOUSE OF REPRESENTATIVES,SENATE", null, 560000, 0, 0, "2018-01-18T14:02:21.110000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2067943"], "units": {}, "query_ms": 97.48784103430808, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}